CRO market poised for growth and consolidation
CROs have seen strong financial results during the past 18 months, reporting higher revenue and a rebound in profit margins, and they expect another year of healthy growth fueled by strategic partnerships with sponsors and an increase in clinical outsourcing.
Strategies for success evolving in phase I space
Nathan Segall, M.D., had high expectations when he opened his phase I clinical trial unit in Atlanta. So did Chad Jaeger, when his employer, Da Vita Clinical Research, expanded in Denver.
To read the full articles for this issue of The CenterWatch Monthly, please click here for subscription information.